Bayer looks for answers with $2bn Askbio acquisition
The German group hopes that boosting its presence in gene therapy will drive growth of its pharma business.
Bristol bets big on Myokardia
The $13.1bn price suggests that Bristol could be banking on mavacamten’s potential outside rare diseases.
Illumina sees the light – or thinks it does
The sequencing group’s $8bn deal to recapture Grail leaves shareholders unimpressed.
Seattle benefits from Merck's long shot
Merck's move on a target that has attracted little attention – Liv-1 – means future data readouts are now eagerly awaited.
Gilead’s cancer ambitions stretch to $21bn
As Immunomedics and Seattle both get backing from the big boys, antibody-drug conjugates finally come of age.
Boehringer hopes schizophrenia apps will Click into place
Licensing deal could enable bundling of antipsychotics with management technology.
Abbvie looks east for CD47
Abbvie signs up China’s I-Mab instead of Trillium, but several other early-stage contenders are looking at the novel immuno-oncology mechanism.
Yumanity finds a shell in Proteostasis
Yumanity Therapeutics wants to be at the forefront of a neurodegenerative disease revolution, but is taking an unglamorous route to get there.
J&J snags novel autoimmune project, and Momenta
The $6.5bn price – biopharma’s biggest buyout of the year so far – shows how competitive the anti-FcRn space has become.
